Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 9/20 | 0.47 |
| ▸ | ECE1 | P42892 | 7/20 | 0.47 |
| ▸ | ANPEP | P15144 | 2/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
| ▸ | MMP9 | P14780 | 1/20 | 0.44 |
| ▸ | MMP8 | P22894 | 1/20 | 0.44 |
| ▸ | MMP14 | P50281 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1764381 | 0.92 | MME (0.55) | MMEECE1ANPEP | |
| SCHEMBL12596612 | 0.92 | MME (0.55) | MMEECE1ANPEP | |
| SCHEMBL1764171 | 0.90 | MME (0.55) | MMEECE1ANPEPMMP2MMP9 | |
| SCHEMBL12596605 | 0.90 | MME (0.55) | MMEECE1ANPEPMMP2MMP9 | |
| SCHEMBL28502829 | 0.87 | MME (0.46) | MMEECE1ANPEPACE | |
| SCHEMBL28502826 | 0.87 | MME (0.49) | MMEECE1ANPEPACE | |
| SCHEMBL13534927 | 0.85 | MMP2 (0.43) | MMEECE1ANPEPMMP2MMP9 | |
| SCHEMBL20526402 | 0.84 | MME (0.55) | MMEECE1ANPEPMMP2MMP9 | |
| SCHEMBL20526398 | 0.83 | ECE1 (0.49) | MMEECE1MMP2MMP9MMP8 | |
| SCHEMBL1763989 | 0.83 | ECE1 (0.54) | MMEECE1MMP2MMP9MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10131681-B2 | Aminophosphinic derivatives that can be used in the treatment of pain | PHARMALEADS (FR) | 2018-11-20 | — | — | US | disclosed |
| US-20140161839-A1 | AMINOPHOSPHINIC DERIVATIVES THAT CAN BE USED IN THE TREATMENT OF PAIN | PHARMALEADS (FR) | 2014-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10131681-B2 | Aminophosphinic derivatives that can be used in the treatment of pain | OPRM1, HRH3, HRH4 | MME 3490/4885ECE1 4097/4885ANPEP 2062/4885 |
| US-20140161839-A1 | AMINOPHOSPHINIC DERIVATIVES THAT CAN BE USED IN THE TREATMENT OF PAIN | OPRM1, HRH3, HRH4 | MME 3490/4885ECE1 4097/4885ANPEP 2062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.